Resistance to molecularly targeted therapy in non-small-cell lung cancer

被引：43
|
作者：
Asao, Tetsuhiko [1 ]
Takahashi, Fumiyuki [1 ]
Takahashi, Kazuhisa [1 ]
机构：
[1] Juntendo Univ, Grad Sch Med, Dept Resp Med, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan
来源：
RESPIRATORY INVESTIGATION | 2019年 / 57卷 / 01期
关键词：
Lung cancer; Molecularly targeted therapy; Acquired resistance; EGFR; ALK; TYROSINE KINASE INHIBITORS; BIM DELETION POLYMORPHISM; ACQUIRED-RESISTANCE; EGFR MUTATIONS; OPEN-LABEL; 1ST-LINE TREATMENT; RESPONSE DURATION; MET AMPLIFICATION; CLINICAL ACTIVITY; T790M MUTATION;
D O I：
10.1016/j.resinv.2018.09.001
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
The discovery of oncogenic driver gene mutations, including epidermal growth factor receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion, ROS proto-oncogene 1 (ROS1) fusion, and ret proto-oncogene (RET) fusion, has led to the development of molecularly targeted therapy for non-small-cell lung cancer (NSCLC). This therapy has changed the standard of care for NSCLC. Despite the dramatic response to molecularly targeted therapy, almost all patients ultimately develop resistance to the drugs. To understand the mechanisms of resistance to molecularly targeted agents, it is essential to understand the molecular pathways of NSCLC. Here, we review the mechanisms of resistance to molecularly targeted therapy and discuss strategies to overcome drug resistance. (C) 2018 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码：20 / 26
页数：7
相关论文
共 50 条
  • [1] Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
    Stinchcombe, Thomas E.
    Ramalingam, Suresh S.
    [J]. LANCET ONCOLOGY, 2010, 11 (06): : 500 - 501
  • [2] Targeted therapy for non-small-cell lung cancer
    Rasul, K. T.
    Al-Khater, A. M.
    [J]. JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH, 2010, 40 (03): : 221 - 221
  • [3] Targeted therapy for non-small-cell lung cancer
    Belani, CP
    [J]. LUNG CANCER, 2004, 45 : S7 - S7
  • [4] Targeted therapy in non-small-cell lung cancer
    Herbst, RS
    [J]. ONCOLOGY-NEW YORK, 2002, 16 (09): : 19 - 24
  • [5] Role of molecularly targeted therapy in the management of advanced non-small-cell lung cancer in the elderly
    Rybacka-Chabros, Barbara
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 : G52 - G55
  • [6] Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer
    Saoirse O. Dolly
    Dearbhaile C. Collins
    Raghav Sundar
    Sanjay Popat
    Timothy A. Yap
    [J]. Drugs, 2017, 77 : 813 - 827
  • [7] Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer
    Dolly, Saoirse O.
    Collins, Dearbhaile C.
    Sundar, Raghav
    Popat, Sanjay
    Yap, Timothy A.
    [J]. DRUGS, 2017, 77 (08) : 813 - 827
  • [8] Molecularly Targeted Therapies in Locally Advanced Non-Small-Cell Lung Cancer
    Devarakonda, Siddhartha
    Morgensztern, Daniel
    Govindan, Ramaswamy
    [J]. CLINICAL LUNG CANCER, 2013, 14 (05) : 467 - 472
  • [9] Targeted therapy in advanced non-small-cell lung cancer
    Gettinger, Scott
    [J]. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 29 (03) : 291 - 301
  • [10] Molecularly Targeted Therapies in Non-Small-Cell Lung Cancer Annual Update 2014
    Morgensztern, Daniel
    Campo, Meghan J.
    Dahlberg, Suzanne E.
    Doebele, Robert C.
    Garon, Edward
    Gerber, David E.
    Goldberg, Sarah B.
    Hammerman, Peter S.
    Heist, Rebecca S.
    Hensing, Thomas
    Horn, Leora
    Ramalingam, Suresh S.
    Rudin, Charles M.
    Salgia, Ravi
    Sequist, Lecia V.
    Shaw, Alice T.
    Simon, George R.
    Somaiah, Neeta
    Spigel, David R.
    Wrangle, John
    Johnson, David
    Herbst, Roy S.
    Bunn, Paul
    Govindan, Ramaswamy
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (01) : S1 - S63
12345